Soclenicant

Soclenicant (BNC210) is an orally active α7 nAChR negative alteration modulator (NAM) with no apparent side effects. Soclenicant exhibits acute anxiolytic activity in rodent models of anxiety. Soclenicant inhibits rat and human α7 nAChR currents (in stably transfected cell lines) induced by acetylcholine, nicotine, choline, and the a7-specific agonist PNU-282987 (HY-12560A) with IC50 values in the range of 1.2 to 3 μM. Soclenicant can be used in studies of anxiety, trauma, and stressor-related disorders[1][2][3][4].

Product Specifications

CAS Number

[1020634-41-6]

Product Name Alternative

BNC210; IW-2143

UNSPSC

12352005

Target

NAChR

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Purity

99.75

Solubility

DMSO : 10 mg/mL (ultrasonic)

Smiles

O=C1C2=CC(NC3CC4=C(C3)C=CC=C4)=CN=C2N(CC)C=C1C(N5CCOCC5)=O

Molecular Formula

C24H26N4O3

Molecular Weight

418.49

References & Citations

[1]Wise T, et al. Cholinergic modulation of disorder-relevant neural circuits in generalized anxiety disorder. Biological psychiatry, 2020, 87 (10) : 908-915.|[2]Hampsey E, et al. BNC210: an investigational α7-nicotinic acetylcholine receptor modulator for the treatment of anxiety disorders. Expert Opin Investig Drugs. 2023 Apr;32 (4) :277-282. |[3]O'Connor SM, et al. BNC210, a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor, demonstrates anxiolytic- and antidepressant-like effects in rodents. Neuropharmacology. 2024 Mar 15;246:109836. |[4]Andriambeloson E, et al. BNC210: A Novel Compound with Potent Anxiolytic Activity[C]//BEHAVIOURAL PHARMACOLOGY. 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA: LIPPINCOTT WILLIAMS & WILKINS, 2007, 18: S16-S16.